Showing 3981-3990 of 7767 results for "".
- Federated Learning Comparable to Traditional Learning Methods for AI-based Melanoma Diagnosishttps://practicaldermatology.com/news/federated-learning-comparable-to-traditional-learning-methods-for-ai-based-melanoma-diagnosis/2462238/A decentralized federated learning approach was comparable in diagnostic performance to traditional centralized and ensemble learning methods in AI-based melanoma diagnosis, new research suggests. Study authors conducted a multicentric, single-arm diagnostic study conducted across six Ger
- Analysis: Inconsistent Pretreatment Testing for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/analysis-inconsistent-pretreatment-testing-for-inflammatory-skin-diseases/2462233/A new analysis of US commercial insurance claims databases indicated that less than 60% of people living with chronic inflammatory skin diseases (CISD) receive recommended pretreatment testing.
- Analysis Reveals Pre- and Post-COVID-19 Teledermatology Usage and Barriershttps://practicaldermatology.com/news/teledermatology-platforms-usage-and-barriers-a-cross-sectional-analysis-of-united-states-based-dermatologists-pre-and-post-covid-19/2462231/Dermatologists have increasingly turned to teledermatology to enhance patient care, but a recent study highlights crucial disparities in platform usage and functionality among practitioners. Researchers used cross-sectional pre-validated survey in 2021 and sought to discern va
- Roflumilast Formulations Show Favorable Tolerability Across Several Trials: Analysishttps://practicaldermatology.com/news/roflumilast-formulations-show-favorable-tolerability-across-several-trials-analysis/2462229/Investigator- and patient-rated assessments indicated that topical roflumilast was tolerable and did not cause discomfort, according to a new analysis of data from several clinical trials.
- Interim Analysis: Tralokinumab Improves Quality of Life in Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/interim-analysis-tralokinumab-improves-quality-of-life-in-moderate-to-severe-atopic-dermatitis/2462224/Tralokinumab, an interleukin-13 (IL-13) inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, was shown to improve several quality of life measures, a 6-month interim analysis sugg
- Long-Term Analysis Shows Upadacitinib Safe Up to 5 Years for Moderate to Severe ADhttps://practicaldermatology.com/news/long-term-analysis-shows-upadacitinib-safe-up-to-5-years-for-moderate-to-severe-ad/2462222/Upadacitinib for the treatment of moderate-to-severe atopic dermatitis (AD) was shown to have an acceptable safety profile at 5 years, according to a new integrated analysis.
- BE HEARD Analysis: Bimekizumab Maintains Treatment Response at 48 Weeks in HShttps://practicaldermatology.com/news/be-heard-analysis-bimekizumab-maintains-treatment-response-at-48-weeks-in-hs/2462220/A pooled analysis of data from the BE HEARD I and BE HEARD II trials presented at Maui Derm 2024 suggested adults with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (BKZ) saw a sustained clin
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <
- New Assessment Tool for Chronic Prurigo Shows Power of Patient Reportinghttps://practicaldermatology.com/news/development-and-validation-of-a-patient-reported-outcome-measure-to-assess-disease-control-in-chronic-prurigo/2462214/Researchers have introduced a 5-item Prurigo Control Test (PCT), in what could be the first patient-reported outcome measure for determining disease control for chronic prurigo (CPG). This tool, according to the researchers, was designed to assess disease control in CPG
- Insufficient Disease Control in Moderate-to-Severe AD: Year-long Longitudinal Study Reveals Treatment Gapshttps://practicaldermatology.com/news/insufficient-disease-control-in-severe-atopic-dermatitis-a-12-month-longitudinal-study-reveals-treatment-gaps/2462212/A recent study presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference highlighted has shed light on the persistent issue of therapeuti